{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T23:59:42Z","timestamp":1770508782316,"version":"3.49.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,19]],"date-time":"2016-02-19T00:00:00Z","timestamp":1455840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.clinthera.2016.02.019","type":"journal-article","created":{"date-parts":[[2016,3,19]],"date-time":"2016-03-19T06:44:30Z","timestamp":1458369870000},"page":"1109-1121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["First Clinical Experience with ONO-4232: A Randomized, Double-blind, Placebo-controlled Healthy Volunteer Study of a Novel Lusitropic Agent for Acutely Decompensated Heart Failure"],"prefix":"10.1016","volume":"38","author":[{"given":"Caroline L.","family":"Ward","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Jamieson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiya","family":"Nabata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Sharpe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Dozono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumitaka","family":"Suto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ihor","family":"Gussak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2016.02.019_bib1","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/CIR.0b013e31829e8807","article-title":"2013 ACCF\/AHA Guideline for the Management of Heart Failure: Executive Summary. A Report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2016.02.019_bib2","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ejheart.2008.08.005","volume":"10","author":"Dickstein","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.clinthera.2016.02.019_bib3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1161\/CIRCHEARTFAILURE.107.746933","article-title":"Admission or changes in renal function during hospitalization for worsening heart failure predict post discharge survival: results from the outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure (OPTIME-CHF)","volume":"1","author":"Klein","year":"2008","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.clinthera.2016.02.019_bib4","first-page":"510","article-title":"Acute Decompensated Heart Failure: contemporary medical management","volume":"36","author":"Joseph","year":"2009","journal-title":"Tex Heart Inst J"},{"key":"10.1016\/j.clinthera.2016.02.019_bib5","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jacc.2008.03.061","article-title":"Heart Failure related hospitalization in the US 1979\u20132004","volume":"52","author":"Fang","year":"2008","journal-title":"JACC"},{"key":"10.1016\/j.clinthera.2016.02.019_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2012.10.002","article-title":"Heart failure","volume":"1","author":"Braunwald","year":"2013","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.clinthera.2016.02.019_bib7","doi-asserted-by":"crossref","first-page":"E786","DOI":"10.1016\/S0735-1097(13)60786-X","article-title":"Prevalence of heart failure by cause in 21 regions: global burden of diseases, injuries and risk factors. Poster presented at ACC 2013","volume":"61","author":"Forouzanfar","year":"2013","journal-title":"JACC"},{"key":"10.1016\/j.clinthera.2016.02.019_bib9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1471-2407-10-105","article-title":"Long-term survival of cancer patients compared to heart failure and stroke: a systematic review","volume":"10","author":"Askoxylakis","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clinthera.2016.02.019_bib10","first-page":"357","article-title":"Association of persistent and transient worsening renal function with mortality risk, readmissions risk, length of stay, and costs in patients hospitalized with acute heart failure","volume":"7","author":"Palmer","year":"2015","journal-title":"ClinicoEcon Outcomes Res"},{"key":"10.1016\/j.clinthera.2016.02.019_bib11","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1161\/01.RES.86.6.663","article-title":"Biphasic Actions of Prostaglandin E2 on the renal afferent arteriole. Role of EP3 and EP4 receptors","volume":"86","author":"Tang","year":"2000","journal-title":"Circ Res"},{"key":"10.1016\/j.clinthera.2016.02.019_bib12","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1161\/HYPERTENSIONAHA.107.088948","article-title":"Prostaglandin E2 induces vascular relaxation by E-prostanoid 4 receptor-mediated activation of endothelial nitric oxide synthase","volume":"50","author":"Hristovska","year":"2007","journal-title":"Hypertension"},{"issue":"8","key":"10.1016\/j.clinthera.2016.02.019_bib13","doi-asserted-by":"crossref","first-page":"e23554","DOI":"10.1371\/journal.pone.0023554","article-title":"Prostaglandin E2 promotes endothelial differentiation from bone marrow-derived cells though AMPK activation","volume":"6","author":"Zhu","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2016.02.019_bib14","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1161\/01.CIR.0000128046.54681.97","article-title":"Prostaglandin E2 Protects the Heart From Ischemia-Reperfusion Injury via Its Receptor Subtype EP4","volume":"109","author":"Xiao","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2016.02.019_bib15","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1160\/TH10-01-0043","article-title":"Selective activation of the prostaglandin E2 receptor subtype EP2 or EP4 leads to inhibition of platelet aggregation","volume":"104","author":"Kuriyama","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinthera.2016.02.019_bib16","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/sj.bjp.0701360","article-title":"Characterization of the prostanoid receptor(s) on human blood monocytes at which prostaglandin E2 inhibits lipopolysaccharide-induced tumour necrosis factor-\u03b1 generation","volume":"122","author":"Meja","year":"1997","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clinthera.2016.02.019_bib17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/cvr\/cvn254","article-title":"Pharmacological activation of the prostaglandin E2 receptor EP4 improves cardiac function after myocardial ischaemia\/reperfusion injury","volume":"81","author":"Hishikari","year":"2009","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.clinthera.2016.02.019_bib18","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/bjp.2008.214","article-title":"Vasorelaxation induced by prostaglandin E2 in human pulmonary vein: role of the EP4 receptor subtype","volume":"154","author":"Foudi","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clinthera.2016.02.019_bib19","first-page":"A12473","article-title":"A Novel Selective EP4 Receptor Agonist Improves Intracellular Ca2+ Handling and Cardiomyocyte Function in Intact Failing Cardiomyocytes. AHA Scientific Sessions 2013","volume":"128","author":"Murakami","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2016.02.019_bib20","first-page":"A15345","article-title":"ONO-4232, an EP4-selective agonist improves left ventricular diastolic dysfunction and ameliorates acute and chronic heart failure in animal models. AHA Scientific Sessions 2012","volume":"126","author":"Kanaji","year":"2012","journal-title":"Circulation"},{"issue":"suppl 1","key":"10.1016\/j.clinthera.2016.02.019_bib21","first-page":"546","article-title":"ONO-4232, an EP4-selective agonist, improves left ventricular diastolic dysfunction in chronic heart failure model. ESC congress 2015","volume":"36","author":"Takahashi","year":"2015","journal-title":"Eur Heart J"},{"issue":"suppl. 1","key":"10.1016\/j.clinthera.2016.02.019_bib22","first-page":"122","article-title":"ONO-4232, a lusitropic EP4 Agonist, preserves PaO2 despite its vasodilating effect. Heart failure 2015; 2nd World Congress on Acute Heart Failure","volume":"17","author":"Kanaji","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.clinthera.2016.02.019_bib23","first-page":"1619","article-title":"Effects of prostacyclin (PGI2) on the hypoxic pulmonary vasoconstriction in dogs","volume":"38","author":"Ishibe","year":"1989","journal-title":"Masui"},{"key":"10.1016\/j.clinthera.2016.02.019_bib24","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/0002-8703(80)90767-X","article-title":"Effects of vasodilators on pulmonary hemodynamics and gas exchange in left ventricular failure","volume":"99","author":"Pierpont","year":"1980","journal-title":"Am Heart J"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816300881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816300881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T02:54:29Z","timestamp":1536893669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291816300881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0149291816300881"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.02.019","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First Clinical Experience with ONO-4232: A Randomized, Double-blind, Placebo-controlled Healthy Volunteer Study of a Novel Lusitropic Agent for Acutely Decompensated Heart Failure","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.02.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}